Perennial Allergic Rhinitis: Current Treatment Approach
Study Objective: To assess the efficacy of Prevalin nasal spray in patients with perennial allergic rhinitis (AR). Study Design: This was an open-label, non-comparative study. Material and Methods: The study population included 30 patients with perennial AR, aged 18 to 64. All patients received Prevalin nasal spray: One spray in each nostril 3 times a day for 21 days. Treatment results were assessed by changes in the clinical symptoms and functional parameters. Results: Clinical benefits were seen in 73.3% of patients. These included restoration of normal nasal breathing, and the reduction of nasal mucosal swelling and the amount of watery nasal discharge. The treatment efficacy was proven by objective findings and patients' subjective assessments. In 26.7% of patients, monotherapy with Prevalin did not produce a clinical effect. Conclusion: Clinically, Prevalin nasal spray was effective in 73.3% of patients with perennial AR.